Analysis – Page 35 – Goldea Capital

Following R3ALM Strategic Acquisition, Vystar Executes Sale of Remaining Vytex Inventory

Written by Customer Service on September 8, 2026. Posted in Public Companies.

BOSTON, MA, Sept. 08, 2026 (GLOBE NEWSWIRE) — Vystar Corporation (OTCQB: VYST) today announced the completion of a sale of substantially all remaining inventory associated with its Vytex business as the Company continues its strategic repositioning following its acquisition of the R3ALM Financial Ecosystem. Vystar CEO Jamie Rotman stated, “I have completed a sale of substantially all remaining Vytex inventory, consisting of 1,395 individual pieces, including toppers, beds, pillows and covers. All of the inventory has now left our warehouse.” The transaction represents another step in Vystar’s efforts to streamline its legacy operations and concentrate resources on the development of the R3ALM ecosystem. Vystar’s Strategic Focus on R3ALM Vystar is increasingly focused on R3ALM and its potential to participate in the rapidly developing...

Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums

Written by Customer Service on September 8, 2026. Posted in Public Companies.

Company invited to present alongside global pharmaceutical, biotechnology and industry leaders at five high-profile U.S. and China conferences in September CEO Abizer Gaslightwala to deliver keynote and featured presentations on next-generation ADC payload innovation and partnerships/collaborations TAMPA, Fla. and LONDON, Sept. 08, 2026 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that the Company has been selected to participate in five prominent oncology, ADC and healthcare industry and investor conferences in the United States and China during September 2026. These speaking engagements position Akari’s proprietary PH1 ADC payload technology in front of leading global pharmaceutical...

QEP Acquires Spray-Lock®, Expanding Its Adhesives Manufacturing Platform

Written by Customer Service on September 8, 2026. Posted in Mergers And Acquisitions.

BOCA RATON, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) — Q.E.P. CO., INC. (OTCQX: QEPC) (the “Company” or “QEP”) today announced that, on September 1, 2026, it completed the acquisition of substantially all of the assets of Spray-Lock, Inc. (“Spray-Lock”), a developer, manufacturer and distributor of premium aerosol spray adhesives for flooring and wall applications. Financial terms of the transaction were not disclosed. The acquisition advances QEP’s strategy of broadening its core adhesives platform by adding Spray-Lock’s patented spray-applied technology, proprietary formulations and technical expertise to QEP’s existing flooring installation solutions. Spray-Lock’s water-based formulations are designed to simplify application, use less adhesive than traditional trowel-applied alternatives and offer moisture and pH tolerance, low-VOC...

Dynagas LNG Partners LP Reports Results for the Three and Six Months Ended June 30, 2026

Written by Customer Service on September 8, 2026. Posted in Earnings Releases And Operating Results.

ATHENS, Greece, Sept. 08, 2026 (GLOBE NEWSWIRE) — Dynagas LNG Partners LP (NYSE: DLNG) (the “Partnership”), an owner of liquefied natural gas (“LNG”) carriers, today announced its results for the three and six months ended June 30, 2026. Half year Highlights:Net Income and Earnings per common unit (basic and diluted) of $33.4 million and $0.82, respectively; Adjusted Net Income(1) of $28.2 million and Adjusted Earnings per common unit(1) (basic and diluted) of $0.68; Adjusted EBITDA(1) of $51.9 million; and 95.7% fleet utilization(2).Quarter Highlights:Net Income and Earnings per common unit (basic and diluted) of $16.0 million and $0.39, respectively; Adjusted Net Income(1) of $15.8 million and Adjusted Earnings per common unit(1) (basic and diluted) of $0.39; Adjusted EBITDA(1) of $27.6 million; 96.2% fleet utilization(2); The...

GreetEat (OTC:GEAT) Announces Growth, Acquisition and Nasdaq Strategy

Written by Customer Service on September 8, 2026. Posted in Public Companies.

GreetEat Corporation Announces 2026–2027 Corporate Growth Roadmap Focused on PCAOB Audit, Strategic Capital, ChefKart Expansion, Acquisitions and Nasdaq Uplisting RENO, Nev., Sept. 08, 2026 (GLOBE NEWSWIRE) — GreetEat Corporation (OTC: GEAT) (“GreetEat” or the “Company”) today announced its strategic corporate roadmap for 2026 and 2027, focused on strengthening the Company’s public-market infrastructure, accessing growth capital, accelerating the development of ChefKart, pursuing strategic acquisitions and positioning GreetEat for a future uplisting to Nasdaq. Management believes GreetEat is entering an important stage of its corporate development and intends to focus on building a scalable, technology-enabled operating platform capable of supporting multiple businesses and future growth opportunities. 2026–2027 STRATEGIC ROADMAP 1....

HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells

Written by Customer Service on September 8, 2026. Posted in Public Companies.

Agreement includes pre-payment commitments for product sales and distribution of the second-generation multi-cytokine-based HCW11-006 for use as a reagent Akron is a leading supplier of critical ancillary materials and accessory molecules for clinical and commercial scale-up of cell, gene and regenerative therapy products HCW Biologics supplies research and cGMP-grade HCW11-006 and Akron markets and distributes the reagent to its established network of research institutions and commercial companies Company showed in studies that CAR-T cells manufactured using HCW11-006 as a reagent exhibited strong anti-tumor activity and enhanced antiviral potency as well as potential for lowering the cost of production of CAR-T therapies MIRAMAR, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ:...

Hyperion DeFi Raises Guidance and Announces $20M Share Repurchase Program

Written by Customer Service on September 8, 2026. Posted in Earnings Releases And Operating Results.

Company Anticipates $7M-$8M FY’26 Adjusted Gross Profit(1), vs. Prior Guidance $5M-$7M Company Anticipates Adjusted Net Operating Cash Flow(4) to Turn Positive in Q3’26 Company Anticipates Generating Positive Core Operating Earnings(3) in Q3’26 Company Announces New $20M Stock Buyback Authorization DALLAS, Sept. 08, 2026 (GLOBE NEWSWIRE) — Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), the first U.S. publicly listed DeFi company building on Hyperliquid, today raised its full-year 2026 guidance and provided new Q3’26 guidance driven by its core operations exceeding management’s prior expectations. In addition, the Company is launching a new $20 million share buyback program. “In the past few weeks, our DeFi businesses have accelerated,” said Hyunsu Jung, CEO of Hyperion DeFi. Mr. Jung continued, “We have now...

Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

Written by Customer Service on September 8, 2026. Posted in Earnings Releases And Operating Results.

RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced clinical updates and financial results for H1 2026. Advances in Clinical Programs Pancreatic Cancer Phase 2a study evaluating Namodenoson in patients with advanced pancreatic ductal adenocarcinoma achieved its primary safety endpoint and demonstrated durable overall survival outcomes. The open-label Phase IIa study enrolled 20 patients with advanced pancreatic ductal adenocarcinoma who had progressed following standard therapies. Fourteen patients received Namodenoson as third-line treatment, five as second-line treatment, and one as fourth-line treatment. Namodenoson was well...

Raymer Elite Reporting Joins Lexitas

Written by Customer Service on September 8, 2026. Posted in Mergers And Acquisitions.

HOUSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) — Lexitas, a leading provider of technology-enabled litigation services and a portfolio company of funds advised by Apax, today announced that Raymer Elite Reporting has joined Lexitas. Founded by Wendy Raymer, Raymer Elite Reporting is a highly respected provider of court reporting and litigation support services, known for its exceptional client service, experienced reporter network, and commitment to delivering accurate and reliable reporting solutions. Serving attorneys, law firms, corporations, and insurers, Raymer Elite has built a strong reputation for professionalism, responsiveness, and quality. “I’m pleased to welcome Raymer Elite Reporting to the Lexitas family,” said Nishat Mehta, CEO of Lexitas. “Wendy has built an outstanding reputation for delivering exceptional service and...

GE Aerospace to Acquire Consolidated Precision Products (CPP), Expanding Mission-Critical Castings Capacity

Written by Customer Service on September 8, 2026. Posted in Mergers And Acquisitions.

CINCINNATI, Sept. 08, 2026 (GLOBE NEWSWIRE) —Investing in castings capacity to support strong demand across commercial engines, aftermarket and defense $11.75 billion transaction, expected to be accretive-a) to adjusted EPS* and free cash flow* in the first year Strong near and long-term value creation for customers and shareholdersGE Aerospace (NYSE:GE) announced today that it has signed an agreement to acquire Consolidated Precision Products (CPP), a leading manufacturer of highly engineered castings, from private investment firms Warburg Pincus and Berkshire Partners. GE Aerospace Chairman and CEO H. Lawrence Culp, Jr., said, “Investing in mission-critical casting capacity is needed to support the strong simultaneous demand across commercial engines, aftermarket and defense. By combining GE Aerospace’s technology capabilities...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals